Dr. Glaspy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
100 UCLA Medical Plaza
Suite 550
Los Angeles, CA 90095Phone+1 310-481-9737Fax+1 310-481-9737- Is this information wrong?
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1985- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1979 - 1983
David Geffen School of Medicine at UCLAClass of 1979
Certifications & Licensure
OR State Medical License 1989 - Present
CA State Medical License 1980 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- Top Doctors:LA Area Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
- Join now to see all
Clinical Trials
- Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma Start of enrollment: 1997 Jul 01
- Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Start of enrollment: 2000 Apr 01
- Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer
- Join now to see all
Publications & Presentations
PubMed
- Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase...Bondarenko, I., Krasnozhon, D., Rutty, D., Chen, J., Fu, Y., Wang, S., Hou, Q., Li, S., Glaspy, J.> ;Supportive Care in Cancer. 2024 Jan 9
- Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: re...Bondarenko, I., Burdaeva, O., Chen, J., Rutty, D., Li, R., Wang, S., Hou, Q., Li, S., Glaspy, J.> ;Supportive Care in Cancer. 2023 Dec 16
- 1 citationsDevelopment of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.Neil A O'Brien, Martina S J McDermott, Jun Zhang, Ke Wei Gong, Ming Lu, Benjamin Hoffstrom, Tong Luo, Raul Ayala, Kevin Chau, Min Liang, Athena M Madrid, Timothy R Don...> ;Molecular Cancer Therapeutics. 2023 Dec 1
- Join now to see all
Press Mentions
Shop TalkFebruary 20th, 2021
Coronavirus Is Forcing Breast Cancer Patients to Make Tough DecisionsApril 12th, 2020
Stand up to Cancer Laura Ziskin Prize Awarded to Drs. Leisha A. Emens and Xiang ZhangJanuary 28th, 2020- Join now to see all
Grant Support
- Resource For Minority Patient RecruitmentNational Cancer Institute2010–2011
- Women'S CancersNational Cancer Institute2009–2011
- Core--Clinical Trial Protocol Review And Monitoring SystemNational Cancer Institute1994–2002
- Randomized Trial Of Peripheral Blood Progenitor Cell (PBPC) MobilizationNational Center For Research Resources1999–2001
- Core--Clinical Material/ProtocolsNational Cancer Institute1995–2000
- Randomized, Placebo-Controlled, Blinded, Phase I/II Trial Of Peg-RhumgdfNational Center For Research Resources1996–1997
- Randomized Trial Of Peripheral Blood Progenitor Cell MobilizationNational Center For Research Resources1996–1997
- Peripheral Blood Progenitor Cells Mobilized By F-Met-HuscfNational Center For Research Resources1995–1996
Hospital Affiliations
Ronald Reagan UCLA Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
